{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:06:14Z","timestamp":1790697974986,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,2,27]],"date-time":"2013-02-27T00:00:00Z","timestamp":1361923200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s00259-013-2369-z","type":"journal-article","created":{"date-parts":[[2013,2,26]],"date-time":"2013-02-26T08:59:36Z","timestamp":1361869176000},"page":"881-888","source":"Crossref","is-referenced-by-count":118,"title":["Role of 18FDG PET\/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours"],"prefix":"10.1007","volume":"40","author":[{"given":"Stefano","family":"Severi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bodei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Sansovini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Ianniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Scarpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Matteucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gilardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Paganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,27]]},"reference":[{"key":"2369_CR1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063\u201372.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2369_CR2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1677\/ERC-10-0152","volume":"17","author":"MB Niederle","year":"2010","unstructured":"Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17(4):909\u201318.","journal-title":"Endocr Relat Cancer"},{"key":"2369_CR3","volume-title":"international Histological classifications of tumours,","author":"E Solcia","year":"2000","unstructured":"Solcia E, Kloppel G, Sobin LH. Histological typing of endocrine tumours. WHO international Histological classifications of tumours, 2nd ed. Berlin: Springer; 2000.","edition":"2"},{"issue":"Suppl 2","key":"2369_CR4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00292-011-1515-2","volume":"32","author":"J L\u00fcttges","year":"2011","unstructured":"L\u00fcttges J. What\u2019s new? The 2010 WHO classification for tumours of the pancreas. Pathologe. 2011;32 Suppl 2:332\u20136.","journal-title":"Pathologe"},{"key":"2369_CR5","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/030089161009600532","volume":"96","author":"G Rindi","year":"2010","unstructured":"Rindi G. The ENETS guidelines: the new TNM classification system. Tumori. 2010;96:806\u20139.","journal-title":"Tumori"},{"key":"2369_CR6","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/s00259-010-1713-9","volume":"38","author":"TC Kwee","year":"2011","unstructured":"Kwee TC, Basu S, Saboury B, Ambrosini V, Torigian DA, Alavi A. A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging. 2011;38:1158\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2369_CR7","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","volume":"16","author":"T Binderup","year":"2010","unstructured":"Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16(3):978\u201385.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2369_CR8","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2967\/jnumed.108.057505","volume":"50","author":"E Garin","year":"2009","unstructured":"Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard AS, Bouriel C, et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009;50(6):858\u201364.","journal-title":"J Nucl Med"},{"issue":"3","key":"2369_CR9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"JC Reubi","year":"2000","unstructured":"Reubi JC, Sch\u00e4r JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273\u201382.","journal-title":"Eur J Nucl Med"},{"key":"2369_CR10","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate: toxicity, efficacy and survival. J Clin Oncol. 2008;26:2124\u201330.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2369_CR11","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","volume":"38","author":"L Bodei","year":"2011","unstructured":"Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2369_CR12","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1677\/ERC-09-0078","volume":"17","author":"DJ Kwekkeboom","year":"2010","unstructured":"Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17(1):R53\u201373.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2369_CR13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/RLU.0b013e318238f111","volume":"37","author":"S Ezziddin","year":"2012","unstructured":"Ezziddin S, Lauschke H, Schaefers M, Meyer C, van Essen M, Biersack HJ, et al. Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors. Clin Nucl Med. 2012;37(1):102\u20134.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"2369_CR14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00944177","volume":"10","author":"S Green","year":"1992","unstructured":"Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10(4):239\u201353.","journal-title":"Invest New Drugs"},{"issue":"10","key":"2369_CR15","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s00259-010-1512-3","volume":"37","author":"I Virgolini","year":"2010","unstructured":"Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET\/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2369_CR16","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","volume":"48","author":"M Gabriel","year":"2007","unstructured":"Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48(4):508\u201318.","journal-title":"J Nucl Med"},{"issue":"5","key":"2369_CR17","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.109.071712","volume":"51","author":"V Ambrosini","year":"2010","unstructured":"Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68Ga-DOTANOC PET\/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51(5):669\u201373.","journal-title":"J Nucl Med"},{"key":"2369_CR18","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/cncr.23469","volume":"112","author":"I Kayani","year":"2008","unstructured":"Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET\/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112:2447\u201355.","journal-title":"Cancer"},{"key":"2369_CR19","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00259-010-1473-6","volume":"37","author":"E Bombardieri","year":"2010","unstructured":"Bombardieri E, Ambrosiani V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:1441\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2369_CR20","doi-asserted-by":"crossref","unstructured":"Sansovini M, Severi S, Ambrosetti A, Monti M, Nanni O, Sarnelli A, et al. Treatment with the radiolabelled somatostatin analog 177Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. Neuroendocrinology. 2013. doi: 10.1159\/000348394","DOI":"10.1159\/000348394"},{"issue":"10","key":"2369_CR21","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","volume":"35","author":"L Bodei","year":"2008","unstructured":"Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35(10):1847\u201356.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"2369_CR22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem EV, et al.; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514\u201323.","journal-title":"N Engl J Med"},{"issue":"4","key":"2369_CR23","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ecl.2010.09.006","volume":"39","author":"S Faivre","year":"2010","unstructured":"Faivre S, Sablin MP, Dreyer C, Raymond E. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors. Endocrinol Metab Clin North Am. 2010;39(4):811\u201326.","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"Suppl 3","key":"2369_CR24","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S0305-7372(10)70026-8","volume":"36","author":"N Fazio","year":"2010","unstructured":"Fazio N, Cinieri S, Lorizzo K, Squadroni M, Orlando L, Spada F, et al. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Cancer Treat Rev. 2010;36 Suppl 3:S87\u201394.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"2369_CR25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","volume":"20","author":"EP Krenning","year":"1993","unstructured":"Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716\u201331.","journal-title":"Eur J Nucl Med."},{"issue":"1","key":"2369_CR26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","volume":"9","author":"IM Modlin","year":"2008","unstructured":"Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61\u201372.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2369_CR27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00259-010-1610-2","volume":"38","author":"S Ezziddin","year":"2011","unstructured":"Ezziddin S, Opitz M, Attassi M, Biermann K, Sabet A, Guhlke S, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2011;38(3):459\u201366.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-013-2369-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-013-2369-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-013-2369-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T23:56:48Z","timestamp":1562716608000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-013-2369-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,27]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["2369"],"URL":"https:\/\/doi.org\/10.1007\/s00259-013-2369-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,27]]}}}